(19)
(11) EP 4 493 726 A1

(12)

(43) Date of publication:
22.01.2025 Bulletin 2025/04

(21) Application number: 23714085.0

(22) Date of filing: 14.03.2023
(51) International Patent Classification (IPC): 
C12Q 1/6886(2018.01)
(52) Cooperative Patent Classification (CPC):
C12Q 1/6886; C12Q 2600/106; C12Q 2600/118; C12Q 2600/158
(86) International application number:
PCT/GB2023/050601
(87) International publication number:
WO 2023/175319 (21.09.2023 Gazette 2023/38)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 15.03.2022 GB 202203588

(71) Applicant: Argonaut Therapeutics Limited
Oxford, Oxfordshire OX4 4GA (GB)

(72) Inventors:
  • LA THANGUE, Nicholas
    Oxford, Oxfordshire OX4 4GA (GB)
  • MUNRO, Shonagh
    Oxford, Oxfordshire OX4 4GA (GB)

(74) Representative: HGF 
HGF Limited 1 City Walk
Leeds LS11 9DX
Leeds LS11 9DX (GB)

   


(54) CANCER DIAGNOSTICS AND TREATMENT BY MEANS OF PRMT5 INHIBITOR